Mylan NV’s planned merger with Pfizer’s Upjohn gets greenlight after drug sell-off
ACCC 2020-09-10 3:50 pm By Alison Eveleigh | Sydney
Please login to bookmark Close

The competition watchdog will not oppose Mylan NV’s proposed merger with Pfizer’s Upjohn Inc after the global pharmaceutical giants agreed to sell several off-patent brands to dispel competition concerns.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au